Eversept Partners LP Buys 353,291 Shares of Celldex Therapeutics, Inc. $CLDX

Eversept Partners LP raised its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 24.6% in the first quarter, Holdings Channel.com reports. The institutional investor owned 1,788,016 shares of the biopharmaceutical company’s stock after buying an additional 353,291 shares during the period. Celldex Therapeutics comprises 3.0% of Eversept Partners LP’s holdings, making the stock its 7th largest position. Eversept Partners LP’s holdings in Celldex Therapeutics were worth $56,716,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after acquiring an additional 680 shares in the last quarter. Millennium Management LLC lifted its position in shares of Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock valued at $7,259,000 after acquiring an additional 306,330 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Celldex Therapeutics by 12.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after purchasing an additional 14,979 shares during the period. Russell Investments Group Ltd. boosted its stake in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares during the period. Finally, Hsbc Holdings PLC purchased a new position in Celldex Therapeutics during the 2nd quarter worth approximately $347,000.

Analyst Ratings Changes

Several brokerages have issued reports on CLDX. Cantor Fitzgerald cut their target price on shares of Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 22nd. Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating and issued a $42.00 price objective on shares of Celldex Therapeutics in a research note on Monday, June 15th. Finally, Canaccord Genuity Group decreased their price objective on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $52.77.

Celldex Therapeutics Stock Up 1.0%

CLDX stock opened at $35.65 on Tuesday. The company has a 50 day moving average of $33.75 and a two-hundred day moving average of $30.78. The company has a market cap of $2.80 billion, a price-to-earnings ratio of -8.37 and a beta of 0.90. Celldex Therapeutics, Inc. has a 12-month low of $19.72 and a 12-month high of $40.30.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.80 million. On average, research analysts anticipate that Celldex Therapeutics, Inc. will post -4.36 EPS for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.